181 related articles for article (PubMed ID: 29869464)
61. Clinical and Analytical Evaluation of the Alinity m HR HPV Assay within the VALGENT-3 Framework.
Dhillon SK; Oštrbenk Valenčak A; Xu L; Poljak M; Arbyn M
J Clin Microbiol; 2021 May; 59(6):. PubMed ID: 33731413
[TBL] [Abstract][Full Text] [Related]
62. Evaluation of YD MolecuTech Real HPV Assay in Comparison with Roche Cobas HPV Assay and BD Onclarity HPV Assay for Detection of HPV Infection.
Park CH; Kim CW; Lee HW; Kwon MJ
Ann Clin Lab Sci; 2024 Mar; 54(2):239-245. PubMed ID: 38802145
[TBL] [Abstract][Full Text] [Related]
63. Comparison of the Cobas 4800 HPV test and the Seeplex HPV4A ACE with the hybrid capture 2 test.
Ki EY; Kim HE; Choi YJ; Park JS; Kang CS; Lee A
Int J Med Sci; 2013; 10(2):119-23. PubMed ID: 23329882
[TBL] [Abstract][Full Text] [Related]
64. HPV testing for cervical cancer screening: technical improvement of laboratory logistics and good clinical performance of the cobas 6800 in comparison to the 4800 system.
Frayle H; Gori S; Rizzi M; Graziani BN; Vian E; Giorgi Rossi P; Del Mistro A
BMC Womens Health; 2019 Mar; 19(1):47. PubMed ID: 30909894
[TBL] [Abstract][Full Text] [Related]
65. [Human papilloma virus genotyping assay using restriction fragment mass polymorphism analysis, and its comparison with sequencing and hybrid capture assays].
Lee EH; Chung HJ; Oh HB; Chi HS; Jee MS; Park SN; Hong SP; Yoo W; Kim SO
Korean J Lab Med; 2007 Feb; 27(1):62-8. PubMed ID: 18094553
[TBL] [Abstract][Full Text] [Related]
66. Evaluation and Optimization of the Clinical Accuracy of Hybribio's 14 High-Risk HPV with 16/18 Genotyping Assay within the VALGENT-3 Framework.
Xu L; Oštrbenk Valenčak A; Poljak M; Arbyn M
J Clin Microbiol; 2020 May; 58(6):. PubMed ID: 32245832
[TBL] [Abstract][Full Text] [Related]
67. Comparative cost analysis of cervical cancer screening programme based on molecular detection of HPV in Spain.
Ibáñez R; Mareque M; Granados R; Andía D; García-Rojo M; Quílez JC; Oyagüez I
BMC Womens Health; 2021 Apr; 21(1):178. PubMed ID: 33902553
[TBL] [Abstract][Full Text] [Related]
68. Development and evaluation of a liquid bead microarray assay for genotyping genital human papillomaviruses.
Feng Q; Cherne S; Winer RL; Balasubramanian A; Lee SK; Hawes SE; Kiviat NB; Koutsky LA
J Clin Microbiol; 2009 Mar; 47(3):547-53. PubMed ID: 19144800
[TBL] [Abstract][Full Text] [Related]
69. Comparison of the Roche Cobas(®) 4800 HPV assay to Digene Hybrid Capture 2, Roche Linear Array and Roche Amplicor for Detection of High-Risk Human Papillomavirus Genotypes in Women undergoing treatment for cervical dysplasia.
Phillips S; Garland SM; Tan JH; Quinn MA; Tabrizi SN
J Clin Virol; 2015 Jan; 62():63-5. PubMed ID: 25542473
[TBL] [Abstract][Full Text] [Related]
70. Clinical performance of the Roche Cobas 4800 HPV test for primary cervical cancer screening in a Chinese population.
Liu SS; Chan KKL; Wei TN; Tse KY; Ngu SF; Chu MMY; Lau LSK; Cheung ANY; Ngan HYS
PLoS One; 2022; 17(8):e0272721. PubMed ID: 35930575
[TBL] [Abstract][Full Text] [Related]
71. Evaluation of a liquid bead array system for high-risk human papillomavirus detection and genotyping in comparison with Hybrid Capture II, DNA chip and sequencing methods.
Cho EJ; Do JH; Kim YS; Bae S; Ahn WS
J Med Microbiol; 2011 Feb; 60(Pt 2):162-171. PubMed ID: 20965919
[TBL] [Abstract][Full Text] [Related]
72. Testing and genotyping of high-risk human papillomavirus by the cobas HPV Test and the Hybrid Capture 2 high-risk HPV DNA test using cervical and vaginal samples.
Pyne MT; Law C; Hillyard DR; Schlaberg R
J Clin Microbiol; 2014 May; 52(5):1720-3. PubMed ID: 24554756
[TBL] [Abstract][Full Text] [Related]
73. Interlaboratory reproducibility and proficiency testing within the human papillomavirus cervical cancer screening program in Catalonia, Spain.
Ibáñez R; Félez-Sánchez M; Godínez JM; Guardià C; Caballero E; Juve R; Combalia N; Bellosillo B; Cuevas D; Moreno-Crespi J; Pons L; Autonell J; Gutierrez C; Ordi J; de Sanjosé S; Bravo IG
J Clin Microbiol; 2014 May; 52(5):1511-8. PubMed ID: 24574284
[TBL] [Abstract][Full Text] [Related]
74. Prevent cervical cancer by screening with reliable human papillomavirus detection and genotyping.
Ge S; Gong B; Cai X; Yang X; Gan X; Tong X; Li H; Zhu M; Yang F; Zhou H; Hong G
Cancer Med; 2012 Aug; 1(1):59-67. PubMed ID: 23342254
[TBL] [Abstract][Full Text] [Related]
75. Development and evaluation of a PCR and mass spectroscopy (PCR-MS)-based method for quantitative, type-specific detection of human papillomavirus.
Patel DA; Shih YJ; Newton DW; Michael CW; Oeth PA; Kane MD; Opipari AW; Ruffin MT; Kalikin LM; Kurnit DM
J Virol Methods; 2009 Sep; 160(1-2):78-84. PubMed ID: 19410602
[TBL] [Abstract][Full Text] [Related]
76. Clinical validation of the cobas 4800 HPV test for cervical screening purposes.
Heideman DA; Hesselink AT; Berkhof J; van Kemenade F; Melchers WJ; Daalmeijer NF; Verkuijten M; Meijer CJ; Snijders PJ
J Clin Microbiol; 2011 Nov; 49(11):3983-5. PubMed ID: 21880968
[TBL] [Abstract][Full Text] [Related]
77. Comparison of DNA testing strategies in monitoring human papillomavirus infection prevalence through simulation.
Lin CY; Li L
BMC Infect Dis; 2016 Nov; 16(1):642. PubMed ID: 27821079
[TBL] [Abstract][Full Text] [Related]
78. Clinical experience with the Cervista HPV HR assay: correlation of cytology and HPV status from 56,501 specimens.
Youens KE; Hosler GA; Washington PJ; Jenevein EP; Murphy KM
J Mol Diagn; 2011 Mar; 13(2):160-6. PubMed ID: 21354050
[TBL] [Abstract][Full Text] [Related]
79. Comparison of AdvanSure HPV GenoBlot and Hybrid Capture 2 assays for detection of HPV infection.
Ko K; Yu S; Kwon MJ; Lee EH; Woo HY; Park H
J Clin Lab Anal; 2018 Jan; 32(1):. PubMed ID: 28205267
[TBL] [Abstract][Full Text] [Related]
80. HPV genotype detection using hybrid capture sample preparation combined with whole genome amplification and multiplex detection with Luminex XMAP.
Lowe B; Kobayashi L; Lorincz A; Mallonee R; O'Neil D; Thai H; Nazarenko I
J Mol Diagn; 2010 Nov; 12(6):847-53. PubMed ID: 20847281
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
